Get the Stockscreener App
1.70
0.29%
0.005
Edesa Biotech Inc stock is traded at $1.70, with a volume of 751.
It is up +0.29% in the last 24 hours and up +0.59% over the past month.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
See More
Previous Close:
$1.695
Open:
$1.7
24h Volume:
751
Relative Volume:
0.00
Market Cap:
$12.48M
Revenue:
-
Net Income/Loss:
$-7.72M
P/E Ratio:
-0.6441
EPS:
-2.6394
Net Cash Flow:
$-6.25M
1W Performance:
-2.86%
1M Performance:
+0.59%
6M Performance:
-13.27%
1Y Performance:
-19.43%
1-Day Range:
$1.70
$1.70
1-Week Range:
$1.67
$1.78
52-Week Range:
$1.55
$4.4899
Edesa Biotech Inc Stock (EDSA) Company Profile
Name
Edesa Biotech Inc
Sector
Industry
Phone
(905) 475-1234
Address
100 SPY COURT, MARKHAM, ON
Compare EDSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
1.70 | 12.41M | 0 | -7.72M | -6.25M | -2.6394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.75 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
734.14 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.05 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
915.48 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.65 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Edesa Biotech Inc Stock (EDSA) Latest News
How buybacks impact Edesa Biotech Inc. stock valueWeekly Stock Recap & Real-Time Volume Surge Alerts - Newser
Edesa Biotech (EDSA) to Release Earnings on Friday - Defense World
Will Edesa Biotech Inc. stock deliver consistent dividendsBond Market & Weekly High Potential Stock Alerts - Newser
Edesa Biotech Inc. (EDSA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Edesa Biotech Inc. stock deliver better than expected guidanceJuly 2025 Chart Watch & Daily Profit Maximizing Trade Tips - newser.com
What technical signals suggest for Edesa Biotech Inc. stock2025 Earnings Impact & Safe Capital Allocation Plans - newser.com
Will Edesa Biotech Inc. stock continue upward momentumJuly 2025 Review & Fast Gaining Stock Reports - newser.com
Edesa Biotech, Inc.Common Shares (NQ: EDSA - Markets Financial Content
Is Edesa Biotech Inc. stock affected by interest rate hikesJuly 2025 Gainers & Free Growth Oriented Trading Recommendations - newser.com
Best data tools to analyze Edesa Biotech Inc. stock2025 Fundamental Recap & Safe Swing Trade Setup Alerts - newser.com
Can Edesa Biotech Inc. stock sustain market leadership2025 Momentum Check & Risk Adjusted Swing Trade Ideas - newser.com
Will Edesa Biotech Inc. stock benefit from sector rotationMarket Rally & Scalable Portfolio Growth Methods - newser.com
Edesa Biotech, Inc. (EDSA) Presents at LSX Investival Showcase Europe 2025Slideshow - Seeking Alpha
Is ESAF Small Finance Bank a Hybrid Growth Value Stock Worth HoldingResistance Zone Identification & Free Stay Informed With Forecasts - earlytimes.in
Is Edesa Biotech Inc a good long term investmentVolatility Adjusted Trading & Free Robust Financial Gains - earlytimes.in
Has Edesa Biotech Inc. found a price floorEarnings Overview Summary & Weekly Breakout Stock Alerts - newser.com
Will Edesa Biotech Inc. stock benefit from green energy trends2025 Short Interest & Safe Capital Growth Tips - Fundação Cultural do Pará
Edesa Biotech Inc Stock Analysis and ForecastEarnings Growth Projections & Investment Risk Management Tips - earlytimes.in
[Form 4] Edesa Biotech, Inc. Insider Trading Activity - Stock Titan
HC Wainwright Raises Earnings Estimates for Edesa Biotech - Defense World
EDSA: EB05 Reduces Risk of Death 25% in Phase 3 ARDS Trial… - MSN
Edesa Biotech Inc Stock (EDSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):